EN / CN

News

Current Position: Home ››  News

08

2025Year02Month

Li Xiang, Deputy Director of the Provincial Department of Industry and Information Technology, Visits Newland Pharmaceutical for Research

On the morning of February 7, Li Xiang, Member of the Party Leadership Group and Deputy Director of the Provincial Department of Industry and Information Technology, led a delegation to the company to investigate the resumption of work and production after the holiday and the operation of the industrial economy. The delegation was accompanied by Zhao Shuhong, Deputy Mayor of Xuchang City, along wi
[View Details]

27

2025Year01Month

Newland Pharmaceutical Recognized as a 2024 National-Level "Green Factory"

Recently, the Ministry of Industry and Information Technology issued the Notice on the Publication of the 2024 Green Manufacturing List. In accordance with the relevant requirements of the Interim Measures for the Tiered Cultivation and Management of Green Factories, and following recommendation by provincial industry and information technology authorities and expert review, Newland Pharmaceutical
[View Details]

07

2024Year11Month

Newland · New Era · New Opportunities · New Leaps — Newland Pharmaceutical 2025–2030 Strategic Consulting Signing Ceremony & Strategy Mobilization Meeting Grandly Held

On the morning of November 5, the signing ceremony for the 2025–2030 Strategic Consulting Service Contract and the Strategy Mobilization Meeting of Newland Pharmaceutical were grandly held at the company's multifunctional hall. Mr. Xie Jianzhong, Chairman of the company, signed the contract on site with Mr. Duan Jidong, Chairman of Shidai Fanglue, a renowned pharmaceutical strategic consultin
[View Details]

10

2024Year10Month

Good News | Ropivacaine Hydrochloride API of Our Company Approved for Market

On October 8, 2024, Newland Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") received the *Approval Notice for the Marketing Application of the Chemical Active Pharmaceutical Ingredient* for Ropivacaine Hydrochloride, approved and issued by the National Medical Products Administration (NMPA). The registration number is Y20220001314, and the notice number is 2024YS01021
[View Details]

27

2024Year09Month

Good News | Our Esomeprazole Sodium API and Tadalafil API Approved for Market

On September 24, 2024, Newland Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") received the Approval Notices for the Marketing Application of Chemical Active Pharmaceutical Ingredients for Esomeprazole Sodium and Tadalafil, approved and issued by the National Medical Products Administration (NMPA).
[View Details]
Total56Items   8 / 12Page  Per Page5Items  First Page  Previous  Next  Last Page